The Indian state of Utter Pradesh reported the highest number of administered doses of the vaccine against the coronavirus (COVID-19) as of November 13, 2023. Furthermore, over 2.2 billion total vaccine doses were administered in India during the same time period.

Vaccination in India were administered since January 16, 2021, with the administration of vaccines to all health care workers in the first phase. In February, the vaccination program was expanded to cover front line workers. The second phase of the program began in March which included citizens above the age of 60 and subsequently, people above the age of 45 with comorbidities. India’s vaccination program currently includes two vaccines, namely, Oxford University – AstraZeneca’s Covidshield vaccine, manufactured by the Serum Institute of India and Bharat Biotech Covaxin. Russia's Sputnik V was expected to be added to the mix starting May 2021.

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

On 6/16/2023 CDPH replaced the booster measures with a new “Up to Date” measure based on CDC’s new recommendations, replacing the primary series, boosted, and bivalent booster metrics The definition of “primary series complete” has not changed and is based on previous recommendations that CDC has since simplified. A person cannot complete their primary series with a single dose of an updated vaccine. Whereas the booster measures were calculated using the eligible population as the denominator, the new up to date measure uses the total estimated population. Please note that the rates for some groups may change since the up to date measure is calculated differently than the previous booster and bivalent measures.

This data is from the same source as the Vaccine Progress Dashboard at https://covid19.ca.gov/vaccination-progress-data/ which summarizes vaccination data at the county level by county of residence. Where county of residence was not reported in a vaccination record, the county of provider that vaccinated the resident is included. This applies to less than 1% of vaccination records. The sum of county-level vaccinations does not equal statewide total vaccinations due to out-of-state residents vaccinated in California.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

Totals for the Vaccine Progress Dashboard and this dataset may not match, as the Dashboard totals doses by Report Date and this dataset totals doses by Administration Date. Dose numbers may also change for a particular Administration Date as data is updated.

Previous updates:

• On March 3, 2023, with the release of HPI 3.0 in 2022, the previous equity scores have been updated to reflect more recent community survey information. This change represents an improvement to the way CDPH monitors health equity by using the latest and most accurate community data available. The HPI uses a collection of data sources and indicators to calculate a measure of community conditions ranging from the most to the least healthy based on economic, housing, and environmental measures.

• Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 16+ and age 5+ denominators have been uploaded as archived tables.

• Starting on May 29, 2021 the methodology for calculating on-hand inventory in the shipped/delivered/on-hand dataset has changed. Please see the accompanying data dictionary for details. In addition, this dataset is now down to the ZIP code level.

India administered over 2.2 billion vaccine doses for the coronavirus (COVID-19) as of October 20, 2022. The number of people infected with the virus was declining across the Asian country. With the onset of the second wave since late March 2021, the central government increased funding to boost vaccination production.

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

On 6/16/2023 CDPH replaced the booster measures with a new “Up to Date” measure based on CDC’s new recommendations, replacing the primary series, boosted, and bivalent booster metrics The definition of “primary series complete” has not changed and is based on previous recommendations that CDC has since simplified. A person cannot complete their primary series with a single dose of an updated vaccine. Whereas the booster measures were calculated using the eligible population as the denominator, the new up to date measure uses the total estimated population. Please note that the rates for some groups may change since the up to date measure is calculated differently than the previous booster and bivalent measures.

This data is from the same source as the Vaccine Progress Dashboard at https://covid19.ca.gov/vaccination-progress-data/ which summarizes vaccination data at the county level by county of residence. Where county of residence was not reported in a vaccination record, the county of provider that vaccinated the resident is included. This applies to less than 1% of vaccination records. The sum of county-level vaccinations does not equal statewide total vaccinations due to out-of-state residents vaccinated in California.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

Totals for the Vaccine Progress Dashboard and this dataset may not match, as the Dashboard totals doses by Report Date and this dataset totals doses by Administration Date. Dose numbers may also change for a particular Administration Date as data is updated.

Previous updates:

• On March 3, 2023, with the release of HPI 3.0 in 2022, the previous equity scores have been updated to reflect more recent community survey information. This change represents an improvement to the way CDPH monitors health equity by using the latest and most accurate community data available. The HPI uses a collection of data sources and indicators to calculate a measure of community conditions ranging from the most to the least healthy based on economic, housing, and environmental measures.

• Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 16+ and age 5+ denominators have been uploaded as archived tables.

• Starting on May 29, 2021 the methodology for calculating on-hand inventory in the shipped/delivered/on-hand dataset has changed. Please see the accompanying data dictionary for details. In addition, this dataset is now down to the ZIP code level.

Out of the two billion COVID-19 vaccines administered, over 1.6 billion vaccines were Covishield vaccine developed by Oxford university and AstraZeneca as of September 1, 2022 in India. Vaccinations in India were administered since January 16, 2021, with the administration of vaccines to all health care workers in the first phase. In February, the vaccination program was expanded to cover front line workers. The second phase of the program began in March which included citizens above the age of 60 and subsequently, people above the age of 45 with comorbidities. India’s vaccination program currently includes three vaccines, namely, Oxford University – AstraZeneca’s Covishield vaccine, manufactured by the Serum Institute of India, Bharat Biotech Covaxin and Russia's Sputnik V.

Despite COVID-19 vaccines being available to pregnant women in India since summer 2021, little is known about vaccine uptake among this high-need population. We conducted mixed methods research with pregnant and recently delivered rural women in northern India, consisting of 300 phone surveys and 15 in-depth interviews, in November 2021. Only about a third of respondents were vaccinated, however, about half of unvaccinated respondents reported that they would get vaccinated now if they could. Fears of harm to the unborn baby or young infant were common (22% of unvaccinated women). However, among unvaccinated women who wanted to get vaccinated, the most common barrier reported was that their healthcare provider refused to provide them with the vaccine. Gender barriers and social norms also played a role, with family members restricting women’s access. Trust in the health system was high, however, women were most often getting information about COVID-19 vaccines from sources that they did..., To understand vaccine uptake, barriers, hesitancy, facilitating factors and sources of trusted information among pregnant and breastfeeding women, we conducted mixed-methods research in northern India in November 2021. In total, we conducted 300 phone surveys and 15 in-depth interviews with women from lower and upper middle-class populations. The eligibility criteria were to include pregnant and recently delivered women who were breastfeeding (up to one year postpartum). The surveys were conducted telephonically. The participants were active members of WhatsApp groups run by a local NGO that was a collaborator on the project. All women in the WhatsApp group were connected to the government health care system, which provides free services. A list of 552 eligible women, from a sample of about 5,000, was provided to the research assistants. Women who were either pregnant or had delivered within 1 year were eligible for the survey. The list included their name, mobile and date of delivery...., The quantitative data are uploaded in Stata format. For other data formats, please contact the study team.Â

India reported almost 45 million cases of the coronavirus (COVID-19) as of October 20, 2023, with more than 44 million recoveries and about 532 thousand fatalities. The number of cases in the country had a decreasing trend in the past months.

Burden on the healthcare system

With the world's second largest population in addition to an even worse second wave of the coronavirus pandemic seems to be crushing an already inadequate healthcare system. Despite vast numbers being vaccinated, a new variant seemed to be affecting younger age groups this time around. The lack of ICU beds, black market sales of oxygen cylinders and drugs needed to treat COVID-19, as well as overworked crematoriums resorting to mass burials added to the woes of the country. Foreign aid was promised from various countries including the United States, France, Germany and the United Kingdom. Additionally, funding from the central government was expected to boost vaccine production.

Situation overview
Even though days in April 2021 saw record-breaking numbers compared to any other country worldwide, a nation-wide lockdown has not been implemented. The largest religious gathering - the Kumbh Mela, sacred to the Hindus, along with election rallies in certain states continue to be held. Some states and union territories including Maharashtra, Delhi, and Karnataka had issued curfews and lockdowns to try to curb the spread of infections.

As of March 6, 2022, Botswana administered a total of around 1.44 million doses of the vaccine against the coronavirus (COVID-19). The country started the vaccination campaign on March 26, 2021, with the first 1,618 doses from Covishield, widely known as AstraZeneca/Oxford vaccine. This was after Namibia received 30 thousand doses on March 9, 2021 from the Serum Institute of India. Moreover, the country received its second batch of AstraZeneca/Oxford vaccines manufactured in South Korea through the COVAX initiative on March 28, 2021.

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 12+ and age 5+ denominators have been uploaded as archived tables.

Starting June 30, 2021, the dataset has been reconfigured so that all updates are appended to one dataset to make it easier for API and other interfaces. In addition, historical data has been extended back to January 5, 2021.

This dataset shows full, partial, and at least 1 dose coverage rates by zip code tabulation area (ZCTA) for the state of California. Data sources include the California Immunization Registry and the American Community Survey’s 2015-2019 5-Year data.

This is the data table for the LHJ Vaccine Equity Performance dashboard. However, this data table also includes ZTCAs that do not have a VEM score.

This dataset also includes Vaccine Equity Metric score quartiles (when applicable), which combine the Public Health Alliance of Southern California’s Healthy Places Index (HPI) measure with CDPH-derived scores to estimate factors that impact health, like income, education, and access to health care. ZTCAs range from less healthy community conditions in Quartile 1 to more healthy community conditions in Quartile 4.

The Vaccine Equity Metric is for weekly vaccination allocation and reporting purposes only. CDPH-derived quartiles should not be considered as indicative of the HPI score for these zip codes. CDPH-derived quartiles were assigned to zip codes excluded from the HPI score produced by the Public Health Alliance of Southern California due to concerns with statistical reliability and validity in populations smaller than 1,500 or where more than 50% of the population resides in a group setting.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

For some ZTCAs, vaccination coverage may exceed 100%. This may be a result of many people from outside the county coming to that ZTCA to get their vaccine and providers reporting the county of administration as the county of residence, and/or the DOF estimates of the population in that ZTCA are too low. Please note that population numbers provided by DOF are projections and so may not be accurate, especially given unprecedented shifts in population as a result of the pandemic.

As of March 9, 2021, India has secured some 2.2 billion COVID-19 vaccine doses through contracts in total. India chose to purchase vaccines manufactured by AstraZeneca (Oxford), Novavax, and the Russian Gamaleya Institute. However, the overwhelming majority of these doses have yet to be produced and delivered. This statistic shows the size of COVID-19 vaccine contracts based on number of doses secured by countries through contracts with manufacturers. The AstraZeneca/Oxford vaccine is by far the most sought COVID-19 vaccine, especially due to its ability to be stored at normal refrigerator temperatures, while other vaccines need ultra cold storage.

Vaccination against SARS-CoV2 is the most important weapon in the arsenal in the battle against COVID-19. There is concern about an increased risk of adverse effects in patients with transfusion-dependent thalassemia (TDT), which affects vaccine acceptance. A predesigned questionnaire was used to evaluate adverse effects (local/systemic within 90 days after vaccination) in participants >18 years of age with TDT. A total of 100 patients received 129 vaccine doses. The mean age of the patients was 24.3 ± 5.7 years and M: F ratio of 1.6:1. Covishield (Serum Institute of India) was administered to 89% of the participants and Covaxin (Bharat Biotech Limited) to 11% of the participants. Adverse effects were documented in 62% of the respondents and were more pronounced after the first dose (52%) compared to the second dose (9%). The most frequent adverse effects were pain at the injection site (43%) and fever (37%). All adverse effects were mild and none of the participants required hospitalization. There were no differences in adverse effects among different vaccines, the presence or absence of comorbidities, blood groups, or ferritin levels. The SARS-CoV2 vaccine appears to be safe in patients with TDT.

This dataset contains a forecast on early availability of doses of the Pfizer-BioNTech vaccine and the AstraZeneca/Oxford vaccine to COVAX Facility participants. The forecast is as at 3 February 2021.

This dataset contains figures on indicative distribution of 240 million doses of the AstraZeneca/Oxford vaccine, licensed to Serum Institute of India (SII) and 96 million doses of the AstraZeneca/Oxford vaccine, under the advance purchase agreement between Gavi, the Vaccine Alliance and AstraZeneca for Q1 & Q2 2021. It also contains an overview of exceptional first round allocation of 1.2 million doses of the WHO Emergency Use Listing (EUL)-approved Pfizer-BioNTech vaccine for Q1 2021.

The data was manually extracted from the The COVAX Facility Interim Distribution Forecast which was announced by COVAX on 3 February 2021.

Vaccination status according to data availability by vaccination documentation.

The isothermal boxes for vaccine market value is pegged at US$ 202.6 million in 2024, with the top 3 countries holding 41% of the market share. Surging demand and transport of vaccines can increase the sales of isothermal boxes at a rate of 5.8% over the next ten years. By following this moderate CAGR, the isothermal box for vaccine industry is supposed to garner US$ 355.8 million by 2034, which is 1.6X of the current market value.

Report Attribute	Details
Isothermal Box for Vaccine Market Size (2024)	US$ 202.6 million
Market Anticipated Forecast Value (2034)	US$ 355.8 million
Market Projected Growth Rate (2024 to 2034)	5.8% CAGR

Country-wise Insights

Regional Market Comparison	CAGR (2024 to 2034)
United States	4.5%
Germany	4.0%
United Kingdom	5.6%
India	7.7%
China	6.9%

Category-wise Insights

Attributes	Details
Top Material Type Segment	Polyethylene (PE)
Total Market Share in 2024 to 2034	44.2%

Attributes	Details
Top Product Type Segment	Long Range
Total Market Share in 2024	66.4%

Isothermal Box for Vaccine Market Report Scope

Attribute	Details
Estimated Market Size (2024)	US$ 202.6 million
Projected Market Size (2034)	US$ 355.8 million
Anticipated Growth Rate (2024 to 2034)	5.8%
Forecast Period	2024 to 2034
Historical Data Available for	2019 to 2023
Market Analysis	US$ million or billion for Value and Units for Volume
Key Regions Covered	North America, Latin America, Europe, Middle East & Africa (MEA), East Asia, South Asia and Oceania
Key Countries Covered	United States, Canada, Brazil, Mexico, Germany, Spain, Italy, France, United Kingdom, Russia, China, India, Australia & New Zealand, GCC Countries, and South Africa
Key Segments Covered	By Product Type, By Material Used, and By Region
Key Companies Profiled	B Medical Systems Sarl AOV International Llp Nilkamal Limited Apex International Blowkings India AUCMA Co., Ltd. EBARA Inc. Termo-Cont MK LLC. CIP Industries cc Gio'Style Lifestyle S.p.A. Coldpack Systems S.A.S.
Report Coverage	Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives
Customization & Pricing	Available upon Request

Executive summary

The novel coronavirus SARS-CoV2 (COVID-19), first detected by Wuhan Municipal Health Commission, China, in Wuhan, Hubei Province in December 2020 and eventually the disease became pandemic. It was declared as Public Health Emergency of International Concern (PHEIC) by WHO in January 2020. The COVID-19 disease primarily spreads through droplets of saliva or discharge from the nose when an infected person coughs or sneezes. People infected with the COVID-19 virus experiences mild, moderate or serious respiratory illness.

Health workers play a critical role in the clinical management of patients with COVID-19 and hence are likely to be the most vulnerable for contracting the disease. Therefore, investigating the extent of infection in health care settings and identifying risk factors for infection among health workers along with follow-up within a facility in which a confirmed case of COVID-19 infection is receiving care can provide useful information on virus transmissibility and routes of transmission, and will bear important step in limiting amplification events in health care facilities.

Objectives:

1. To find out the extent of human-to-human transmission of the SARS-CoV-2 infection among health workers
2. To study the clinical presentations of COVID-19 infection and the risk factors for infection among health workers.
3 To evaluate the effectiveness of infection prevention and control measures among health workers in protecting against COVID-19.
4. To evaluate the effectiveness of infection prevention and control programmes at health facility level
5. To determine the serological response of health workers with symptomatic and possibly asymptomatic COVID-19 infection.

Materials and Methods:

This was a prospective cohort study conducted over a period of seven months, from December 2020 to June 2021, the period covering India’s deadly second wave of COVID-19 pandemic. This was done among the health care workers working in HIMSR & HAHC hospital, a tertiary health care setting (Dedicated COVID-19 Hospital) providing care to patients with a laboratory-confirmed COVID-19 infection. This hospital located in South East Delhi has 200 bedded COVID-19 Care Hospital and 1050 registered healthcare workers who come in contact with COVID-19-infected persons. The study population (sampling frame) included all the health personnel like doctors, nurses, paramedical staff, housekeeping staff, security staff, students of medical, nursing and paramedical sciences and other front office staff who come in contact with the patients. In this study, the first visit / interview (Baseline) was done when the staff came in contact with a confirmed COVID-19 case. The second visit / interview (Endline) was done between 22-28 days. During each of these two visits, biological sample in the form of serum was collected to check the presence of anti-COVID-19 antibodies

Results:

A total of 192 HCW were recruited in this study. All of them were interviewed and blood was collected for serology at the baseline visit as well as at endline. Out of 192 participants, 119 (61.97%) were detected with SARS-CoV2 antibodies at baseline whereas 73 (38.02%) were seronegative. Again, on22-28 days of follow-up, the seropositivity was 77.7% at the endline. We found that seropositivity was significantly and negatively associated with doctor as profession [OR:0.353, CI:0.176-0.710], COVID-19 symptoms [OR:0.210, CI:0.054-0.820], comorbidities [OR:0.139 , CI: 0.029 - 0.674], recent IPC Training [OR:0.250, CI:0.072 -0.864] , while positively associated with Partially [OR:3.303,CI: 1.256-8.685], as well as fully Vaccinated for COVID-19 [OR:2.428, CI:1.118-5.271]. We also observed seroconversion among 36.7% while 64.0% had increase in titre of antibodies during our follow-up period. The seroconversion was 63.2% in doctors, 42.9% in nurses and 13.0% in paramedics staff. Seroconversion was positively associated with doctor as profession [OR:11.43, CI:2.47 - 52.79] and with partially, as well as fully vaccinated for COVID-19 [OR: 32.63, CI: 5.11 - 208.49]. None of the HCW who were smokers and with any comorbidity did not found to have been seroconversion. We observe a negative and significant relationship of increase in titre of antibodies with recent any ILI symptoms [OR:0.17, 0.13 - 0.94], smokers[OR: 0.35, 95%CI: 0.13 - 0.94], HCW with comorbidities [OR:0.08,95CI: 0.01 - 0.71],, recent full IPC Training [OR:0.07, CI:0.01 -0.63] , while positively associated with partially [OR: 7.87, 95CI: 2.18 - 28.40)], as well as fully Vaccinated for COVID-19 [OR: 3.59, 95CI: 1.46 - 8.87]. Majority of the health care worker enrolled in our study had close contact exposure with COVID-19 patients while 5 had indirect exposure. It was observed that almost all (100% in both) doctors and nurses as well as almost all paramedical staff (99%) were wearing some kind of personal protective equipment (PPE) when they were exposed to a COVID-19 patient. We did not found adherences to any of the infection prevention measure adopted by the enrolled HCW during the recent contact with COVID-19 patients to be significantly associated with seroconversion.

Conclusion:

Majority of the health care worker (67% doctor, 80% nurses & 55% paramedics) enrolled in our study had close contact exposure with COVID-19 patient. The results show that among 192 HCW enrolled, 62% were seropositive at the baseline. At end line the seropositivity was increased to 77.7%. The seroconversion rate was also studied. It was found to be 36.7% in our study population (63.2% in doctors, 42.9% in nurses and 13.0% in paramedic’s staff.). Adherence to the recommended IPC measures was reported by most participants. About two third (63%) of the HCW in our study were not vaccinated against COVID-19; nurses and paramedics were higher in proportion among those who were unvaccinated. Fifteen percentage were partially vaccinated and 22% were fully vaccinated against COVID-19, with doctors comprising majority among them. We also found that vaccination had the strongest association with seropositivity, seroconversion as well as serial rise of titre.

As of February 21, 2022, Eswatini administered a total of 490.9 thousand doses of the vaccine against the coronavirus (COVID-19). On March 31, 2021, 3,377 doses of Covishield, widely known as AstraZeneca/Oxford vaccine, were distributed. This was after the country received 32 thousand doses, of which 12 thousand were via the COVAX initiative on March 12, 2021, while the rest originated from a donation from India.

The global pneumococcal vaccines market is projected to have an average-paced CAGR of 4.1% during the forecast period. The current valuation of the market is US$ 8.9 Billion in 2023. The market value of the pneumococcal vaccines market is anticipated to surpass a market valuation of US$ 13.3 Billion by 2033. A historical market valuation of US$ 8.5 Billion has been recorded by the analysts of Future Market Insights for the concerned market during the base year.

Report Attribute	Details
Pneumococcal Vaccines Market Value (2023)	US$ 8.9 Billion
Pneumococcal Vaccines Market Anticipated Value (2033)	US$ 13.3 Billion
Pneumococcal Vaccines Projected Growth Rate (2023 to 2033)	4.1%

PCV in Infant Routine Immunization in 2023 Excel Against the Historical Market Scenario

Historical CAGR (2018 to 2022)	3.2%
Market Value in 2022	US$ 8.5 Billion

Forecast CAGR (2023 to 2033)	4.1%
Market Value in 2023	US$ 8.9 Million

Country-wise Insights

Region	North America
Country	United States of America
CAGR (2023 to 2033)	1.8%

Region	Europe
Country	United Kingdom
CAGR (2023 to 2033)	2.5%

Region	Europe
Country	Germany
CAGR (2023 to 2033)	2.9%

Region	Asia Pacific
Country	China
CAGR (2023 to 2033)	9.0%

Region	Asia Pacific
Country	India
CAGR (2023 to 2033)	9.2%

The vaccines market is likely to strengthen its boundaries at an average CAGR of 6.6% during the forecast period. The market is expected to hold a value of US$ 42.7 billion in 2023 while it is anticipated to cross a value of US$ 80.8 billion by 2033.

Attributes	Details
Vaccines Market CAGR (2023 to 2033)	6.6%
Vaccines Market Size (2023)	US$ 42.7 billion
Vaccines Market Size (2033)	US$ 80.8 billion

Vaccines Market Country-wise Insights

Regions	Absolute Market Growth
United States	US$ 14.8 billion
United Kingdom	US$ 1.5 billion
China	US$ 3.5 billion
Japan	US$ 2.3 billion
India	US$ 1.3 billion

United States Market CAGR (2023 to 2033)	6.6%
United States Market Absolute Doller Growth (US$ million/billion)	US$ 14.8 billion

Region	Attributes
Chinese Market CAGR (2023 to 2033)	8.9%
Chinese Market Absolute Doller Growth (US$ million/billion)	US$ 3.5 billion

Category-wise Insights

Segment	Top Vaccine Type
Top Sub-segment	Subunit & Conjugate
CAGR (2017 to 2022)	5.8%
CAGR (2023 to 2033)	7.3%

Segment	Route of Administration
Top Sub-segment	Injectable
CAGR (2017 to 2022)	6.0%
CAGR (2023 to 2033)	6.7%

Snapshot img

Influenza Vaccine Market Size 2024-2028

The influenza vaccine market size is forecast to increase by USD 3.76 billion at a CAGR of 8.09% between 2023 and 2028. The market is experiencing significant growth due to the increasing prevalence and incidence of severe influenza cases, particularly among children. The Global Influenza Program's emphasis on vaccination as a preventative measure is driving market expansion. Combination vaccines, which offer protection against multiple strains of the virus, are gaining popularity due to their convenience and effectiveness. Furthermore, the development of mRNA vaccines, which utilize advanced technology to produce a more potent immune response, is a promising trend in the market. The market for Influenza vaccines encompasses various types, including inactivated vaccines, live attenuated vaccines, quadrivalent vaccines, mono vaccine, trivalent vaccines, pnemucoccol vaccine, pediatric vaccines, and adult vaccines. Despite these advancements, challenges persist, including the difficulty in diagnosing influenza due to its non-specific symptoms and the need for annual revaccination to maintain immunity. Overall, the market is poised for continued growth as the demand for effective vaccines to prevent the spread of influenza remains high.

Market Analysis

Request Free Sample

The market is a significant sector within the global healthcare industry, with a continuous demand due to the seasonal nature of the influenza virus and the ongoing threat of potential pandemics. This market caters to various demographics, including children and adults, through various vaccine types and administration methods. Seasonal influenza vaccines are the primary focus of the market, with two main types: inactivated vaccines and live attenuated vaccines. Inactivated vaccines, also known as flu shots, use killed viruses to stimulate an immune response, while live attenuated vaccines, or nasal sprays, use weakened live viruses.

Furthermore, both types offer protection against the three or four strains of the virus predicted to cause the most significant impact during a season. Quadrivalent vaccines, a more recent addition to the market, protect against an additional B strain, broadening the scope of coverage and potentially reducing the risk of infection. Trivalent vaccines, which protect against three strains, continue to be available and are often used in mass vaccination programs. The pediatric segment of the market is of significant importance due to the vulnerability of children to severe influenza cases. The global influenza program, a collaborative effort between the World Health Organization (WHO) and various national health organizations, plays a crucial role in ensuring the availability of vaccines for children and other at-risk populations.

In addition, combination vaccines, which offer protection against influenza and other diseases, are gaining popularity in the market due to their convenience and potential for reducing the number of vaccinations required. MRNA vaccines, a newer technology, have shown promising results in clinical trials and may become a significant player in the market in the coming years. The market is influenced by several factors, including the severity of seasonal epidemics, the availability and affordability of vaccines, and the public's perception of vaccine efficacy and safety. Hospital and retail pharmacies serve as essential distribution channels for these vaccines, ensuring they reach the end consumer in a timely and convenient manner.

Furthermore, swine flu vaccines, while not a regular component of the seasonal the market, are produced and distributed in response to outbreaks or pandemics. The production and distribution of these vaccines require a rapid response and significant resources, highlighting the importance of a strong global influenza program and the flexibility of vaccine manufacturers. In conclusion, the market is a dynamic and evolving sector within the healthcare industry. With ongoing research and development, the market continues to offer new solutions to protect against the influenza virus, ensuring public health and safety.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Distribution Channel

  Hospitals and pharmacies
  Government and institutional
  Others


Type

  Live attenuated influenza vaccines
  Recombinant influenza vaccines


Geography

  North America

    Canada
    US


  Europe

    UK


  Asia

    China
    India


  Rest of World (ROW)

By Distribution Channel Insights

The hospitals and pharmacies segment is estimated to witness significant growth during the forecast period.The market in the US is categorized by distributio

Seroprevalence of 67.6% is used with 765 million infectionsa from an age-adjusted population as of 14 Jun-6 Jul 2021 from the 4th nationwide serosurvey [6].